PVLA Latest Press Releases

-- August 5, 2026 --

Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference Globe Newswire 7:30 AM

-- August 4, 2026 --

Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 7:30 AM

-- July 30, 2026 --

Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing Globe Newswire 7:30 AM

-- July 28, 2026 --

Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026 Globe Newswire 7:30 AM

-- June 30, 2026 --

Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors Globe Newswire 7:30 AM

-- June 29, 2026 --

Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations Globe Newswire 7:30 AM

-- June 22, 2026 --

FDA Grants Rolling Review of Palvella's QTORIN Rapamycin NDA for Microcystic Lymphatic Malformations Globe Newswire 7:30 AM

-- June 9, 2026 --

ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors PRNewswire 8:43 AM

-- June 3, 2026 --

Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN Rapamycin in Microcystic Lymphatic Malformations Globe Newswire 7:30 AM

-- June 2, 2026 --

Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 Globe Newswire 7:30 AM

-- May 27, 2026 --

Palvella Therapeutics Strengthens QTORIN Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043 Globe Newswire 7:30 AM

-- May 21, 2026 --

Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards Globe Newswire 7:30 AM

-- May 20, 2026 --

Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations Globe Newswire 4:30 PM

-- May 15, 2026 --

Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology Globe Newswire 7:30 AM

-- May 13, 2026 --

Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market Globe Newswire 7:30 AM

-- May 7, 2026 --

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 7:30 AM

-- May 4, 2026 --

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN Rapamycin for Clinically Significant Angiokeratomas Globe Newswire 7:30 AM

-- April 30, 2026 --

Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026 Globe Newswire 7:30 AM

-- April 20, 2026 --

Palvella Therapeutics to Present QTORIN Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026 Globe Newswire 7:30 AM

-- April 13, 2026 --

Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors Globe Newswire 7:30 AM

-- April 7, 2026 --

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales Globe Newswire 7:30 AM

-- March 31, 2026 --

Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update Globe Newswire 7:30 AM

-- March 30, 2026 --

Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations Globe Newswire 7:30 AM

-- March 27, 2026 --

Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting Globe Newswire 10:30 AM

-- March 24, 2026 --

Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 Globe Newswire 7:30 AM

-- March 23, 2026 --

Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services Globe Newswire 7:30 AM